High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform

Maryou B K Lambros, Paul M Wilkerson, Rachael Natrajan, Neill Patani, Vidya Pawar, Radost Vatcheva, Marthe Mansour, Mirja Laschet, Beatrice Oelze, Nicholas Orr, Susanne Muller, Jorge S Reis-Filho

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Fusion genes have pivotal roles in the development and progression of human cancer and offer potential for rational drug design. Massively parallel sequencing has identified a panoply of in-frame expressed fusion genes, but early reports suggest that the majority of these are present at very low prevalence or are private events. Conventional methods for the identification of recurrent expressed fusion genes in large cohorts of cancers (eg fluorescence in situ hybridization (FISH) and reverse transcriptase PCR (RT-PCR)) are time consuming and prone to artifacts. Here, we describe a novel high-throughput strategy for the detection of recurrent fusion genes in cancer based on the Sequenom MassARRAY platform. Fusion genes were initially identified by massively parallel sequencing of breast cancer cell lines. For each fusion gene, two Sequenom probes were designed. Primary human breast cancers and cancer cell lines were interrogated for 10 fusion genes. Sensitivity, specificity, and predictive values of the MassARRAY method were then determined using FISH and qRT-PCR as the 'gold standard.' By combining two probes per fusion gene, the negative and positive predictive values were 100 and 71.4%, respectively. All fusion genes identified by massively parallel sequencing were accurately detected. No recurrent fusion genes were found. The MassARRAY-based approach described here may, therefore, be employed as a high-throughput screening tool for known fusion genes in human cancer. In keeping with other highly sensitive assays, further refinement of this technique is necessary to reduce the number of false-positive results.

Original languageEnglish
Pages (from-to)1491-501
Number of pages11
JournalLaboratory investigation
Volume91
Issue number10
DOIs
Publication statusPublished - Oct 2011

Keywords

  • Breast Neoplasms
  • Cell Line, Tumor
  • Female
  • Genetic Testing
  • HeLa Cells
  • High-Throughput Nucleotide Sequencing
  • Humans
  • In Situ Hybridization, Fluorescence
  • Microarray Analysis
  • Oncogene Proteins, Fusion
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Evaluation Studies
  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform'. Together they form a unique fingerprint.

  • Cite this

    Lambros, M. B. K., Wilkerson, P. M., Natrajan, R., Patani, N., Pawar, V., Vatcheva, R., Mansour, M., Laschet, M., Oelze, B., Orr, N., Muller, S., & Reis-Filho, J. S. (2011). High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform. Laboratory investigation, 91(10), 1491-501. https://doi.org/10.1038/labinvest.2011.110